|
Characteristics of medical inpatients receiving enoxaparin versus UFH prophylaxis |
|||
| Prophylaxis Received |
|||
|
|
|||
| Characteristic |
Enoxaparin |
UFH |
p-value |
|
|
|||
| N |
479 |
2,837 |
|
| Age (Mean [Range]) |
75.6 (40–98) |
71.8 (40–101) |
<0.001 |
| Age group [n (%)]: |
|||
| 40–49 years |
30 (6.3) |
185 (6.5) |
<0.001 |
| 50–59 years |
39 (8.1) |
414 (14.6) |
|
| 60–69 years |
67 (14) |
527 (18.6) |
|
| 70–79 years |
131 (27.3) |
850 (30.0) |
|
| 80–89 years |
165 (34.4) |
687 (24.2) |
|
| 90+ years |
47 (9.8) |
174 (6.1) |
|
| Female [n (%)] |
285 (59.5) |
1,506 (53.1) |
0.009 |
| White [n (%)] |
449 (93.7) |
2,302 (81.1) |
<0.001 |
| Principal diagnosis [n (%)]: |
|||
| Circulatory |
215 (44.9) |
1,349 (47.6) |
0.062 |
| Respiratory |
150 (31.3) |
926 (32.6) |
|
| Acute Infection |
70 (14.6) |
296 (10.4) |
|
| Neoplasm |
44 (9.2) |
266 (9.4) |
|
| Risk factors for VTE [n (%)]: |
|||
| CHF |
194 (40.5) |
810 (28.6) |
<0.001 |
| COPD |
156 (32.6) |
826 (29.1) |
0.126 |
| Receipt of HRT |
19 (4.0) |
127 (4.5) |
0.615 |
| Obesity (coded as medical condition) |
21 (4.4) |
123 (4.3) |
0.962 |
| Inflammatory bowel disease |
3 (0.6) |
6 (0.2) |
0.129 |
| Fracture of lower limb |
3 (0.6) |
3 (0.1) |
0.043 |
| Nephrotic syndrome |
1 (0.2) |
5 (0.2) |
1.000 |
| Geographic region of hospital [n (%)]: |
|||
| Northeast |
374 (78.1) |
1,227 (43.2) |
<0.001 |
| Midwest |
21 (4.4) |
681 (24.0) |
|
| South |
79 (16.5) |
916 (32.3) |
|
| West |
5 (1.0) |
13 (0.5) |
|
| Hospital size [n (%)]: |
|||
| < 200 beds |
30 (6.3) |
214 (7.5) |
<0.001 |
| 200–499 beds |
273 (57.0) |
864 (30.5) |
|
| 500+ beds |
176 (36.7) |
1,759 (62.0) |
|
| Teaching hospital [n (%)] |
260 (54.3) |
2,235 (78.8) |
<0.001 |
|
VTE = venous thromboembolism, CHF = congestive heart failure, COPD = chronic obstructive pulmonary disease, HRT = hormone replacement therapy | |||
McGarry et al. Thrombosis Journal 2006 4:17 doi:10.1186/1477-9560-4-17 |
|||